1. Home
  2. TY vs GLPG Comparison

TY vs GLPG Comparison

Compare TY & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tri Continental Corporation

TY

Tri Continental Corporation

N/A

Current Price

$32.00

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Logo Galapagos NV

GLPG

Galapagos NV

N/A

Current Price

$31.45

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TY
GLPG
Founded
1929
1999
Country
United States
Belgium
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.1B
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
TY
GLPG
Price
$32.00
$31.45
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
$31.33
AVG Volume (30 Days)
43.0K
89.8K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
3.36%
N/A
EPS Growth
N/A
N/A
EPS
4.78
N/A
Revenue
N/A
$336,643,201.00
Revenue This Year
N/A
$3.61
Revenue Next Year
N/A
N/A
P/E Ratio
$6.38
N/A
Revenue Growth
N/A
10.31
52 Week Low
$25.16
$22.36
52 Week High
$30.73
$37.78

Technical Indicators

Market Signals
Indicator
TY
GLPG
Relative Strength Index (RSI) 26.72 49.43
Support Level $34.54 $30.73
Resistance Level $35.05 $32.75
Average True Range (ATR) 0.37 0.56
MACD -0.30 0.02
Stochastic Oscillator 1.76 39.26

Price Performance

Historical Comparison
TY
GLPG

About TY Tri Continental Corporation

Tri-Continental Corp is a United States-based closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: